Repair Stem Cell Institute Says Stanford University's Stem Cell Study Confirms The Futility Of Embryonics In Human Therapy

Main Category: Stem Cell Research
Article Date: 29 Aug 2008 - 3:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

The Repair Stem Cell Institute LLC (RSCI; http://www.RepairStemCells.org) reported that Stanford University School of Medicine's recent discovery there may be limitations to the effectiveness of human therapies derived from embryonic stem cells (ESC) because the cells injected in mice stimulated the kind of immune rejection seen with transplanted organs clearly delivers a blow to proponents of embryonic stem cell research who continue to ballyhoo the promise of ESC when in effect, as the Stanford study showed, the transplanted stem cells were dead within about seven to 10 days.

According to Don Margolis, founder and chairman of the RSCI, "The new Stanford findings further confirm the futility of embryonics in human therapy despite what proponents of human ESC research have been promising, that transplanted ESC can mature into several different types of tissue. Those cells could not survive in the mouse, suggesting the same would likely occur in a patient." He noted a statement from Stanford radiologist Dr. Joseph Wu, part of the research team: "I think there's some promise [to human ESCs] but you don't want to be foolish and say these cells are going to cure things in the next five years."

Mr. Margolis said in addition to the Stanford findings presenting difficulties to one day permit human trials, the U.S. Food and Drug Administration has not approved "the injection of ESCs into patients because they also have the potential to become cancerous."

He also said, "With over 100 diseases already being treated with Repair Stem Cells by the world's finest doctors, the need for further ESC research merely to add to 10 years of futility is called into question."

Visit http://www.RepairStemCells.org/StemCellTreatmentCenters.php for RSCI's global listing of stem cell treatment centers and the practitioners meeting its standards of excellence who are already treating those 100+ medical conditions with success.

About the RSCI

The Repair Stem Cell Institute LLC is a global independent public service company dedicated to bringing the news about Repair Stem Cell treatments to the public. The RSCI was founded in April 2008 and is based in Bangkok with administrative headquarters in Dallas and a communications, government and public affairs office in Washington.

The Repair Stem Cell Institute LLC
http://www.RepairStemCells.org